Comparative Efficacy of Biologics As Monotherapy and in Combination with Methotrexate on Patient Reported Outcomes (PROs) in Rheumatoid Arthritis Patients with an Inadequate Response to Conventional DMARDs--a Systematic Review and Network...

Overview

Journal Health Qual Life Outcomes

Publisher Biomed Central

Specialty Public Health

Date 2014 Jul 4

PMID 24988902

Citations 28

Authors

Jeroen P Jansen

Felicity Buckley

Fred Dejonckheere

Sarika Ogale

Affiliations

Soon will be listed here.

Abstract

Objective: To compare biologics as monotherapy or in combination with methotrexate (MTX) in terms of patient reported outcomes (PROs) in RA patients with an inadequate response to conventional DMARDs (DMARD-IR).

Methods: With a systematic literature review 17 RCTs were identified that evaluated adalimumab, certolizumab pegol, etanercept, golimumab, infliximab, abatacept, anakinra or tocilizumab. Treatment effects in terms of pain (0-100 mm), patient's global assessment of disease activity (PGA; 0-100 mm), Health Assessment-Questionnaire (HAQ) disability index (DI; 0-3), and the physical component summary (PCS) of the SF36 Health Survey (0-100) at 24 weeks were combined by means of Bayesian network meta-analyses.

Results: With tocilizumab monotherapy, greater improvements in pain (difference = -11.1; (95% Credible Interval -21.3, -0.1)) and PGA (-10.3 (-20.4, 0.8)) were observed than with aTNF monotherapy. Tocilizumab was at least as efficacious as aTNF in HAQ-DI improvements (-0.16; (-0.37, 0.05)). aTNF + MTX (-17.9 (-23.1, -13.0) & -19.1 (-24.2, -14.4)), abatacept + MTX (-23.0 (-47.3, 1. 5) & -13.6 (-28.4, 2.0)) and tocilizumab + MTX (-16.0 (-26.3, -6.3) & -15.1 (-25.1, -5.7)) showed comparable reductions in pain and PGA relative to MTX. Efficacy of anakinra + MTX was much smaller as compared to other biologics. The greatest improvements in HAQ-DI relative to MTX were observed with aTNF + MTX (-0.30 (-0.37, -0.22)) and tocilizumab + MTX (-0.27 (-0.42, -0.12)), followed by abatacept + MTX (-0.21 (-0.37, -0.05)) and anakinra + MTX (-0.11 (-0.26, 0.05)). The improvements in SF36-PCS with abatacept + MTX, aTNF + MTX and tocilizumab + MTX were comparable. There is a >90% probability that aTNF + MTX results in a greater improvement in pain (-12.4), PGA (-16.1) and HAQ-DI (-0.21) than aTNF as monotherapy. Efficacy of tocilizumab + MTX showed comparable improvements in PROs as tocilizumab monotherapy.

Conclusions: Based on a network meta-analysis involving indirect comparison of trial findings, the following observations were made for DMARD-IR patients. In monotherapy, tocilizumab was associated with a greater improvement in pain and self-reported disease activity than aTNF, and was at least as efficacious regarding functional ability. The improvements in PROs with aTNF, abatacept and tocilizumab in combination with MTX were comparable. Improvements in PROs with tocilizumab as monotherapy were similar to that of tocilizumab + MTX, whereas aTNF as monotherapy was likely to be less efficacious than aTNF + MTX.

Citing Articles

Pharmacological pain management in patients with rheumatoid arthritis: a narrative literature review.

Cox N, Mallen C, Scott I BMC Med. 2025; 23(1):54.

PMID: 39881356 PMC: 11780779. DOI: 10.1186/s12916-025-03870-0.

Pain management in people with inflammatory arthritis: British Society for Rheumatology guideline scope.

Scott I, Babatunde O, Barker C, Beesley R, Beesley R, Birkinshaw H Rheumatol Adv Pract. 2024; 8(4):rkae128.

PMID: 39563967 PMC: 11573413. DOI: 10.1093/rap/rkae128.

Potential Mechanism of Fatigue Induction and Its Management by JAK Inhibitors in Inflammatory Rheumatic Diseases.

Felis-Giemza A, Massalska M, Roszkowski L, Romanowska-Prochnicka K, Ciechomska M J Inflamm Res. 2023; 16:3949-3965.

PMID: 37706062 PMC: 10497048. DOI: 10.2147/JIR.S414739.

Exploring the impact of the national tender system on the use of costly drugs treating rheumatoid arthritis patients in ten rheumatology centers in Norway (2010-2019).

Brkic A, Diamantopoulos A, Hoff M, Haavardsholm E, Fevang B, Brekke L BMC Health Serv Res. 2023; 23(1):968.

PMID: 37679747 PMC: 10486045. DOI: 10.1186/s12913-023-09975-7.

Inflammasomes: Mechanisms of Action and Involvement in Human Diseases.

Bulte D, Rigamonti C, Romano A, Mortellaro A Cells. 2023; 12(13).

PMID: 37443800 PMC: 10340308. DOI: 10.3390/cells12131766.

References

Smolen J, Beaulieu A, Rubbert-Roth A, Ramos-Remus C, Rovensky J, Alecock E . Effect of interleukin-6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis (OPTION study): a double-blind, placebo-controlled, randomised trial. Lancet. 2008; 371(9617):987-97. DOI: 10.1016/S0140-6736(08)60453-5. View

Caldwell D, Ades A, Higgins J . Simultaneous comparison of multiple treatments: combining direct and indirect evidence. BMJ. 2005; 331(7521):897-900. PMC: 1255806. DOI: 10.1136/bmj.331.7521.897. View

Felson D, Anderson J, Boers M, Bombardier C, Chernoff M, Fried B . The American College of Rheumatology preliminary core set of disease activity measures for rheumatoid arthritis clinical trials. The Committee on Outcome Measures in Rheumatoid Arthritis Clinical Trials. Arthritis Rheum. 1993; 36(6):729-40. DOI: 10.1002/art.1780360601. View

Kremer J, Genant H, Moreland L, Russell A, Emery P, Abud-Mendoza C . Effects of abatacept in patients with methotrexate-resistant active rheumatoid arthritis: a randomized trial. Ann Intern Med. 2006; 144(12):865-76. DOI: 10.7326/0003-4819-144-12-200606200-00003. View

Wells G, Li T, Maxwell L, Maclean R, Tugwell P . Determining the minimal clinically important differences in activity, fatigue, and sleep quality in patients with rheumatoid arthritis. J Rheumatol. 2007; 34(2):280-9. View

Lipsky P, van der Heijde D, St Clair E, Furst D, Breedveld F, Kalden J . Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group. N Engl J Med. 2000; 343(22):1594-602. DOI: 10.1056/NEJM200011303432202. View

Luqmani R, Hennell S, Estrach C, Basher D, Birrell F, Bosworth A . British Society for Rheumatology and British Health Professionals in Rheumatology guideline for the management of rheumatoid arthritis (after the first 2 years). Rheumatology (Oxford). 2009; 48(4):436-9. DOI: 10.1093/rheumatology/ken450a. View

Bergman G, Hochberg M, Boers M, Wintfeld N, Kielhorn A, Jansen J . Indirect comparison of tocilizumab and other biologic agents in patients with rheumatoid arthritis and inadequate response to disease-modifying antirheumatic drugs. Semin Arthritis Rheum. 2010; 39(6):425-41. DOI: 10.1016/j.semarthrit.2009.12.002. View

Wells G, Tugwell P, Kraag G, Baker P, Groh J, Redelmeier D . Minimum important difference between patients with rheumatoid arthritis: the patient's perspective. J Rheumatol. 1993; 20(3):557-60. View

10.

van de Putte L, Atkins C, Malaise M, Sany J, Russell A, Van Riel P . Efficacy and safety of adalimumab as monotherapy in patients with rheumatoid arthritis for whom previous disease modifying antirheumatic drug treatment has failed. Ann Rheum Dis. 2004; 63(5):508-16. PMC: 1755008. DOI: 10.1136/ard.2003.013052. View

11.

Hoaglin D, Hawkins N, Jansen J, Scott D, Itzler R, Cappelleri J . Conducting indirect-treatment-comparison and network-meta-analysis studies: report of the ISPOR Task Force on Indirect Treatment Comparisons Good Research Practices: part 2. Value Health. 2011; 14(4):429-37. DOI: 10.1016/j.jval.2011.01.011. View

12.

Jansen J, Fleurence R, Devine B, Itzler R, Barrett A, Hawkins N . Interpreting indirect treatment comparisons and network meta-analysis for health-care decision making: report of the ISPOR Task Force on Indirect Treatment Comparisons Good Research Practices: part 1. Value Health. 2011; 14(4):417-28. DOI: 10.1016/j.jval.2011.04.002. View

13.

Schiff M, Keiserman M, Codding C, Songcharoen S, Berman A, Nayiager S . Efficacy and safety of abatacept or infliximab vs placebo in ATTEST: a phase III, multi-centre, randomised, double-blind, placebo-controlled study in patients with rheumatoid arthritis and an inadequate response to methotrexate. Ann Rheum Dis. 2007; 67(8):1096-103. PMC: 2564802. DOI: 10.1136/ard.2007.080002. View

14.

Strand V, Mease P, Burmester G, Nikai E, Coteur G, van Vollenhoven R . Rapid and sustained improvements in health-related quality of life, fatigue, and other patient-reported outcomes in rheumatoid arthritis patients treated with certolizumab pegol plus methotrexate over 1 year: results from the RAPID 1 randomized.... Arthritis Res Ther. 2009; 11(6):R170. PMC: 3003523. DOI: 10.1186/ar2859. View

15.

Cole J, Motivala S, Khanna D, Lee J, Paulus H, Irwin M . Validation of single-factor structure and scoring protocol for the Health Assessment Questionnaire-Disability Index. Arthritis Rheum. 2005; 53(4):536-42. DOI: 10.1002/art.21325. View

16.

Weinblatt M, Kremer J, Bankhurst A, Bulpitt K, Fleischmann R, Fox R . A trial of etanercept, a recombinant tumor necrosis factor receptor:Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate. N Engl J Med. 1999; 340(4):253-9. DOI: 10.1056/NEJM199901283400401. View

17.

Launois R, Avouac B, Berenbaum F, Blin O, Bru I, Fautrel B . Comparison of certolizumab pegol with other anticytokine agents for treatment of rheumatoid arthritis: a multiple-treatment Bayesian metaanalysis. J Rheumatol. 2011; 38(5):835-45. DOI: 10.3899/jrheum.100665. View

18.

Jadad A, Moore R, Carroll D, Jenkinson C, Reynolds D, Gavaghan D . Assessing the quality of reports of randomized clinical trials: is blinding necessary?. Control Clin Trials. 1996; 17(1):1-12. DOI: 10.1016/0197-2456(95)00134-4. View

19.

Weinblatt M, Keystone E, Furst D, Moreland L, Weisman M, Birbara C . Adalimumab, a fully human anti-tumor necrosis factor alpha monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: the ARMADA trial. Arthritis Rheum. 2003; 48(1):35-45. DOI: 10.1002/art.10697. View

20.

Cohen S, Moreland L, Cush J, Greenwald M, Block S, Shergy W . A multicentre, double blind, randomised, placebo controlled trial of anakinra (Kineret), a recombinant interleukin 1 receptor antagonist, in patients with rheumatoid arthritis treated with background methotrexate. Ann Rheum Dis. 2004; 63(9):1062-8. PMC: 1755108. DOI: 10.1136/ard.2003.016014. View